This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2005;23(10):967-9.

doi: 10.2165/00019053-200523100-00001.

Transparency in economic evaluations

PMID: 16235971
DOI: 10.2165/00019053-200523100-00001

Editorial

Transparency in economic evaluations

Suzanne Hill. Pharmacoeconomics. 2005.

. 2005;23(10):967-9.

doi: 10.2165/00019053-200523100-00001.

Author

PMID: 16235971
DOI: 10.2165/00019053-200523100-00001

No abstract available

PubMed Disclaimer

Similar articles

Meandering down the road to transparency.
Carswell CI, Paladino JA. Carswell CI, et al. Pharmacoeconomics. 2008;26(3):179-80. doi: 10.2165/00019053-200826030-00001. Pharmacoeconomics. 2008. PMID: 18282012 No abstract available.
Transparency of economic evaluations of health technologies.
Rovira J. Rovira J. Pharmacoeconomics. 2008;26(3):181-3. doi: 10.2165/00019053-200826030-00002. Pharmacoeconomics. 2008. PMID: 18282013 No abstract available.
Pharmacoeconomics: integrating economic evaluation into clinical trials.
Haycox A, Drummond M, Walley T. Haycox A, et al. Br J Clin Pharmacol. 1997 Jun;43(6):559-62. doi: 10.1046/j.1365-2125.1997.00576.x. Br J Clin Pharmacol. 1997. PMID: 9205814 Free PMC article. Review. No abstract available.
Evaluating the quality of published pharmacoeconomic evaluations.
Sanchez LA. Sanchez LA. Hosp Pharm. 1995 Feb;30(2):146-8, 151-2. Hosp Pharm. 1995. PMID: 10140528 No abstract available.
Improving drug trials for mild to moderate Alzheimer's disease.
Hogan DB. Hogan DB. Can J Neurol Sci. 2007 Mar;34 Suppl 1:S97-102. doi: 10.1017/s0317167100005655. Can J Neurol Sci. 2007. PMID: 17469691 Review.

See all similar articles

Cited by

A review of health care models for coronary heart disease interventions.
Cooper K, Brailsford SC, Davies R, Raftery J. Cooper K, et al. Health Care Manag Sci. 2006 Nov;9(4):311-24. doi: 10.1007/s10729-006-9996-x. Health Care Manag Sci. 2006. PMID: 17186767 Review.
Meandering down the road to transparency.
Carswell CI, Paladino JA. Carswell CI, et al. Pharmacoeconomics. 2008;26(3):179-80. doi: 10.2165/00019053-200826030-00001. Pharmacoeconomics. 2008. PMID: 18282012 No abstract available.
Reporting pharmacoeconomic evaluations.
Carswell CI, Paladino JA. Carswell CI, et al. Pharmacoeconomics. 2005;23(11):1073. doi: 10.2165/00019053-200523110-00001. Pharmacoeconomics. 2005. PMID: 16277544 No abstract available.

References

1. Eur J Health Econ. 2004 Oct;5(3):263-9 - PubMed
1. JAMA. 1999 Oct 20;282(15):1453-7 - PubMed
1. JAMA. 2003 Aug 20;290(7):921-8 - PubMed
1. Emerg Med J. 2002 Jul;19(4):301-4 - PubMed
1. BMJ. 2002 Feb 9;324(7333):313-4 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer